Wed, Jan 28, 2015, 2:13 PM EST - U.S. Markets close in 1 hr 47 mins

Recent

% | $
Quotes you view appear here for quick access.

Marina Biotech, Inc. Message Board

btimnextmicrosoft 79 posts  |  Last Activity: Jan 27, 2015 12:35 PM Member since: Oct 15, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • United States patent 8,815804 – Claims in this case relate to peptides that selectively home to tumors, blood clots and/or other injury sites in a subject and are potentially useful in targeting cells to cancer as a novel therapeutic strategy. The patent is licensed to BioTime’s subsidiary OncoCyte Corporation. A European patent has previously issued in this family, with national patents granted in Finland, France, Germany, Ireland, Lithuania, Luxenbourg, Monaco, Netherlands, Sweden, Switzerland and the UK. Additional applications pending in multiple jurisdictions.

  • btimnextmicrosoft btimnextmicrosoft Jan 27, 2015 12:30 PM Flag

    In-licensed Patents:

    United States patent 8921104 – The patent titled, “Method for Producing Dendritic Cells,” claims methods relating to embryonic stem cell-derived dendritic cells. Dendritic cells are cells that present molecules to the immune system in order to trigger an immune response to that particular protein. BioTime’s subsidiary Asterias Biotherapeutics is developing hES cell-derived dendritic cells modified to trigger an immune response to certain antigens related to cancer. Patents in the same family have previously issued in the United States (3 others issued), China and Australia, with additional applications pending in multiple jurisdictions.

    United States patent 8,815804 – Claims in this case relate to peptides that selectively home to tumors, blood clots and/or other injury sites in a subject and are potentially useful in targeting cells to cancer as a novel therapeutic strategy. The patent is licensed to BioTime’s subsidiary OncoCyte Corporation. A European patent has previously issued in this family, with national patents granted in Finland, France, Germany, Ireland, Lithuania, Luxenbourg, Monaco, Netherlands, Sweden, Switzerland and the UK. Additional applications pending in multiple jurisdictions.

  • btimnextmicrosoft btimnextmicrosoft Jan 27, 2015 12:29 PM Flag

    Singapore patent 176957 – The patent titled, “Differentiated Pluripotent Stem Cell Progeny Depleted of Extraneous Phenotypes,” claims methods for the purification of pluripotent stem cell-derived oligodendrocytes by the removal of contaminating cells that display an antigen called epithelial cell adhesion molecule (EpCAM). This method is potentially useful in the purification of such oligodendrocytes prior to their use in research or human therapy. Patents in the same family have previously issued in the United States and China, with additional applications pending.

    Singapore patent 177694 – The patent titled, “Methods and Compositions for in vitro and in vivo Chondrogenesis,” claims methods for the manufacture of cartilage from BioTime’s PureStem® cell lines 4D20.8, SM30, E15, MEL2, SK11, and 7SMOO32, methods for combining the cells with matrices, and molding the cartilage to produced formed tissue. The patent is potentially useful for BioTime’s subsidiary OrthoCyte Corporation in the manufacture of human cartilage grafts for the repair of orthopedic disorders such as arthritis and degeneration of the intervertebral disc. A patent in the same family has previously issued in the United States, with additional applications pending.

  • btimnextmicrosoft btimnextmicrosoft Jan 27, 2015 12:25 PM Flag

    South Korea patent 1543500B – The patent titled, “Hematopoietic Cells from Human Embryonic Stem Cells,” claims methods for using pluripotent stem cell technology for inducing immune tolerance of cells transplanted into a patient (that is, in helping to prevent the rejection of transplanted cells). As such, the patent claims may be useful in commercializing diverse types of transplantable cells. Patents in the same family have previously issued in Australia, UK, Israel, Japan and Singapore, with additional applications pending.

    Canada patent 2468335 – The patent describes cartilage-forming cells derived from human pluripotent stem cells such as hES cells. The claims in the patent relate to a system of making the cartilage-forming cells using factors of the transforming growth factor beta (TGF-beta) family, of immortalizing the cells with the human telomerase gene, pharmaceutical formulations of the cells for therapeutic use in arthritis, as well as other claims. The patent is therefore useful for the manufacture of such cells for use in research and potentially in therapy for a number of applications in orthopedic medicine. Patents in the same family have previously issued in the United States, Australia, Singapore, Israel and South Korea, with additional applications pending.

  • btimnextmicrosoft btimnextmicrosoft Jan 27, 2015 12:24 PM Flag

    New Patents Owned by BioTime or one of its subsidiaries:

    European patent 1809739 – This issued patent claims cell culture media for the proliferation and scale-up of hES cells. The patent issuing in Austria, France, Germany, Ireland, Switzerland and Sweden provides a propagation medium for culturing hES cells in the laboratory such that the cells proliferate without differentiating as defined in the claims. The technology allows the user to rapidly produce high-quality embryonic stem cells for use in therapy and drug discovery, in a cost-effective and controlled manner, from defined or commercially available reagents. The patent is therefore useful for manufacturing products from hES cells. Patents in the same family have previously issued in the United States, Australia, UK, Israel, Singapore and Hong Kong, with additional applications pending.

    Canada patent 2559854 and China patent ZL200580008779.0 – These patents claim a differentiation method for making high purity heart muscle preparations from pluripotent stem cells such as hES cells suitable for use in regenerative medicine. The issued claims cover methods wherein the pluripotent stem cells are treated with specific growth factors and differentiation conditions to manufacture beating heart muscle cells. The patents are therefore useful in the manufacture and commercialization of heart muscle cells for research, for the testing of drugs on the heart, and potentially for regenerating heart muscle following a heart attack or heart failure. Patents in the same family have previously issued in the United States, Australia, UK, Israel, Japan and Singapore, with additional applications pending.

  • BioTime, Inc. (NYSE MKT: BTX) announced today the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc. (NYSE MKT: AST), OrthoCyte Corporation, ES Cell International Pte Ltd, OncoCyte Corporation, and ReCyte Therapeutics, Inc. The new patents issued over Q3 and Q4 of 2014 add to the BioTime family of companies’ patent estate of over 600 patents and patent applications pending worldwide, which is the largest known patent estate in the field of pluripotent stem cell technology for human therapeutic application, an emerging field known as “regenerative medicine.”

  • btimnextmicrosoft by btimnextmicrosoft Jan 26, 2015 3:13 PM Flag

    hESC+ECM+dendritic=$$$

  • btimnextmicrosoft by btimnextmicrosoft Jan 20, 2015 3:04 PM Flag

    Enjoy your short day!

  • I would think he would use this momentum to kick it into second gear!

  • btimnextmicrosoft by btimnextmicrosoft Jan 13, 2015 12:56 PM Flag

    2012 ICELL deal:


    2015 BTX deal:


    Could be wrong but seems like BIotimes deal to be more of a 'two way street'. Both BTX and ICELL being run by pioneers in the stem sector, so it's interesting to see how these companies expand going forward. Dr. West has had more biz experience with forming Geron and running ACTC, so I think his biz dimension is a definite advantage.
    Icell's deal with fertility clinic looks interesting, as far as I know BTX looking at more 'off the shelf' applications for stem cells. Still in all this is a wide open playing field with both companies leading the way.

    Btw, I posted hear because BTX starting to be overrun by headless investors and thought there might be more substantial dialogue over here.
    My 2cents

  • 5 yr chart shows only one small step for BTX.

  • Reply to

    Shorts

    by short_buster Jan 12, 2015 7:57 PM
    btimnextmicrosoft btimnextmicrosoft Jan 12, 2015 8:01 PM Flag

    baltbear better sell his yacht!

  • Reply to

    Investor Presentation

    by twicesilent23 Jan 12, 2015 9:26 AM
    btimnextmicrosoft btimnextmicrosoft Jan 12, 2015 2:21 PM Flag

    Thx for heads up on GE partner presentation!

  • Reply to

    AST again hirgher then the mothership!

    by ipstissueface Jan 12, 2015 11:52 AM
    btimnextmicrosoft btimnextmicrosoft Jan 12, 2015 2:20 PM Flag

    It's not hurting but I'd say Biotimes climb is mainly due to the fact that they are by far the leader in the stem sector and investors are finally starting to notice. Also GE partnership two weeks ago doesn't hurt as well as all the bigwig ex-big pharma jumping on the board over last month or so. And let's not forget our two huge low hanging fruits on their way to the market.

  • Reply to

    AST again hirgher then the mothership!

    by ipstissueface Jan 12, 2015 11:52 AM
    btimnextmicrosoft btimnextmicrosoft Jan 12, 2015 12:19 PM Flag

    No worries BTX owns a piece of the action, and will own an even bigger part of the action with OncoCytes IPO!

  • Reply to

    healthy poolback today

    by mriucd Jan 9, 2015 11:26 AM
    btimnextmicrosoft btimnextmicrosoft Jan 9, 2015 11:43 AM Flag

    Partnering with GE not news??!!! Shorts gonna get burned when we have PanC-DX or LifeMap Medical app news early next week.

  • Reply to

    Is this a short squeeze?

    by blueharvestmoon Jan 8, 2015 2:05 PM
    btimnextmicrosoft btimnextmicrosoft Jan 8, 2015 3:57 PM Flag

    The GE partnership announced last week didn't hurt.

  • Reply to

    Huge Trades at the close

    by wallstreetguys Jan 7, 2015 4:10 PM
    btimnextmicrosoft btimnextmicrosoft Jan 8, 2015 3:52 PM Flag

    Big money wants big returns, if these big trades came in at around $4, then I'd say we are in for some huge upsides in 2015.

  • btimnextmicrosoft btimnextmicrosoft Jan 8, 2015 3:40 PM Flag

    Biotimes OncoCyte will diagnose cancer with PanC-DX and BTX's AST will treat cancers with dendritic stem cell vaccines. 1-2 punch!

  • btimnextmicrosoft by btimnextmicrosoft Jan 8, 2015 3:11 PM Flag

    Can't wait to hear how this personalized medical app will tie into PanC-DX. Patients cancer genetic marker prognosis explained via smart phone!

MRNA
0.63-0.0348(-5.23%)1:49 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.